BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1054 related articles for article (PubMed ID: 8771506)

  • 1. Left ventricular dysfunction after heart transplantation: incidence and role of enhanced immunosuppression.
    McNamara D; Di Salvo T; Mathier M; Keck S; Semigran M; Dec GW
    J Heart Lung Transplant; 1996 May; 15(5):506-15. PubMed ID: 8771506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-ischemic left ventricular dysfunction after pediatric cardiac transplantation: treatment with plasmapheresis and OKT3.
    McOmber D; Ibrahim J; Lublin DM; Saffitz JE; Ong-Simon C; Mendeloff EN; Huddleston CB; Canter CE
    J Heart Lung Transplant; 2004 May; 23(5):552-7. PubMed ID: 15135370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolution of focal moderate (International Society for Heart and Lung Transplantation grade 2) rejection of the cardiac allograft.
    Milano A; Caforio AL; Livi U; Bauce B; Angelini A; Casarotto D; Thiene G
    J Heart Lung Transplant; 1996 May; 15(5):456-60. PubMed ID: 8771500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between bridging with ventricular assist device on rejection after heart transplantation.
    Pamboukian SV; Costanzo MR; Dunlap S; Rayburn B; Westfall AO; You ZY; Hung E; McLeod M; Heroux A
    J Heart Lung Transplant; 2005 Mar; 24(3):310-5. PubMed ID: 15737758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of methotrexate on acute rejection and cardiac allograft vasculopathy in heart transplant recipients.
    Costanzo MR; Koch DM; Fisher SG; Heroux AL; Kao WG; Johnson MR
    J Heart Lung Transplant; 1997 Feb; 16(2):169-78. PubMed ID: 9059928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of steroid-resistant and recurrent acute cardiac transplant rejection with a short course of antibody therapy.
    Cantarovich M; Latter DA; Loertscher R
    Clin Transplant; 1997 Aug; 11(4):316-21. PubMed ID: 9267721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ventricular assist devices and aggressive immunosuppression: looking beyond overall survival.
    Gonzalez-Stawinski GV; Cook DJ; Chang AS; Banbury MK; Navia JL; Hoercher K; Lober C; Atik FA; Taylor DO; Yamani MH; Young JB; Starling RC; Smedira NG
    J Heart Lung Transplant; 2006 Jun; 25(6):613-8. PubMed ID: 16730565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic impact of immunosuppression and cellular rejection on cardiac allograft vasculopathy: time for a reappraisal.
    Mehra MR; Ventura HO; Chambers RB; Ramireddy K; Smart FW; Stapleton DD
    J Heart Lung Transplant; 1997 Jul; 16(7):743-51. PubMed ID: 9257256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. OKT3 induction and steroid-free maintenance immunosuppression for treatment of high-risk heart transplant recipients.
    Prieto M; Lake KD; Pritzker MR; Jorgensen CR; Arom KV; Love KR; Emery RW
    J Heart Lung Transplant; 1991; 10(6):901-11. PubMed ID: 1661608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Short- and long-term course of heart transplantation recipients with severe dysfunction of the graft associated with acute rejection].
    Anguita M; Arizón JM; Vallés F; López-Rubio F; Latre JM; Giménez D; Torres F; Concha M
    Rev Esp Cardiol; 1994 Jun; 47(6):384-8. PubMed ID: 8066310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose cyclosporine treatment fails to prevent coronary luminal narrowing after heart transplantation.
    Vassalli G; Kaski JC; Tousoulis D; Kiowski W; Turina M; Follath F; Gallino A
    J Heart Lung Transplant; 1996 Jun; 15(6):612-9. PubMed ID: 8794036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of mild rejection of the cardiac allograft.
    Yeoh TK; Frist WH; Eastburn TE; Atkinson J
    Circulation; 1992 Nov; 86(5 Suppl):II267-71. PubMed ID: 1424011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methotrexate or total lymphoid radiation for treatment of persistent or recurrent allograft cellular rejection: a comparative study.
    Ross HJ; Gullestad L; Pak J; Slauson S; Valantine HA; Hunt SA
    J Heart Lung Transplant; 1997 Feb; 16(2):179-89. PubMed ID: 9059929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ten-year follow-up of a prospective, randomized trial of BT563/bb10 versus anti-thymocyte globulin as induction therapy after heart transplantation.
    Bonaros N; Dunkler D; Kocher A; Imhof M; Grimm M; Zuckermann A; Wolner E; Laufer G
    J Heart Lung Transplant; 2006 Sep; 25(9):1154-63. PubMed ID: 16962480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular abnormalities and cardiomyocyte lipofuscin deposits in endomyocardial biopsy specimens of heart transplant recipients: are they related to the development of cardiac allograft vasculopathy?
    Zakliczynski M; Nozynski J; Konecka-Mrowka D; Krynicka-Mazurek A; Swierad M; Maruszewski M; Przybylski R; Zembala M
    J Thorac Cardiovasc Surg; 2009 Jul; 138(1):215-21, 221.e1-3. PubMed ID: 19577082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intermediate term results of infant orthotopic cardiac transplantation from two centers.
    Backer CL; Zales VR; Harrison HL; Idriss FS; Benson DW; Mavroudis C
    J Thorac Cardiovasc Surg; 1991 May; 101(5):826-32. PubMed ID: 1902539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term follow-up of heart transplant recipients treated with murine antihuman mature T cell monoclonal antibody (OKT3): the Loyola experience.
    Costanzo-Nordin MR; O'Sullivan EJ; Hubbell EA; Zucker MJ; Pifarre R; McManus BM; Winters GL; Scanlon PJ; Robinson JA
    J Heart Transplant; 1989; 8(4):288-95. PubMed ID: 2504895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction immunosuppressive therapy is associated with a low rejection rate after liver transplantation.
    McVicar JP; Kowdley KV; Emond MJ; Barr D; Marsh CL; Carithers RL; Perkins JD
    Clin Transplant; 1997 Aug; 11(4):328-33. PubMed ID: 9267724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of an elevated B-type natriuretic peptide to predict allograft failure, cardiac allograft vasculopathy, and survival after heart transplantation.
    Mehra MR; Uber PA; Potluri S; Ventura HO; Scott RL; Park MH
    Am J Cardiol; 2004 Aug; 94(4):454-8. PubMed ID: 15325928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The duration of administration of monoclonal antibody OKT3 for induction immunosuppression after heart transplantation.
    Aleksic I; Freimark D; Blanche C; Czer LS; Dalichau H; Valenza M; Takkenberg JJ; Trento A
    Thorac Cardiovasc Surg; 1997 Aug; 45(4):190-5. PubMed ID: 9323821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.